Navigation Links
Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males
Date:5/19/2009

Specially designed microsite (www.meettheburns.com) targets first time athlete's foot sufferers and parents.

KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the arrival of TINACTIN(R) CHILL, an antifungal spray for the treatment of athlete's foot. TINACTIN CHILL is available in two formulations, liquid spray and deodorant powder spray.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 )

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/tinactin/38431/

Athlete's foot is an infection caused by direct contact with fungus. People are most susceptible when their feet are sweating or when wearing shoes that lack proper ventilation. The condition is commonly picked up by walking barefoot in locker rooms, pools and other public areas.

TINACTIN CHILL is targeted to address the needs of the first time athlete's foot sufferer, which are primarily young males ages 14 to 22. "Research shows that experiencing athlete's foot for the first time can be very frightening and intimidating for young men," said John O'Mullane, PhD., group vice president, research and development, Schering-Plough Consumer Healthcare. "Our research indicated that to reach this age group we would need to go beyond the traditional methods of communication with our customers."

To reach this audience, Schering-Plough developed an innovative Web site, www.meettheburns.com. The site features a series of "Webisodes" highlighting the fictitious Burns family and a character named "Gus" representing fungus. Each segment presents an athlete's foot treatment message in a situation comedy style that is entertaining and identifies well with teens. "Many young men are reluctant to talk about their situation when they first experience athlete's foot," O'Mullane said. "However, they often seek information on the Internet. By developing this Web site, we can reach young men and help inform them and their parents that there are effective and easy to use treatments for this common condition."

About TINACTIN CHILL

TINACTIN CHILL is clinically proven to cure most athlete's foot and can even help prevent athlete's foot with daily use. The Liquid Spray contains ingredients that provide an extra cooling sensation and the Deodorant Powder Spray will fight odor all day long in addition to treating athlete's foot.

TINACTIN CHILL is available at most mass retailers, drugstores, grocery stores and online outlets.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough, an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: